Patents by Inventor Dechun Li

Dechun Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190262422
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Application
    Filed: January 9, 2018
    Publication date: August 29, 2019
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • Patent number: 9878005
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: January 30, 2018
    Assignee: The Johns Hopkins University
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • Patent number: 9763100
    Abstract: An instant messaging message processing method is disclosed and includes: receiving, by a server, an instant messaging message, user account information of a destination user terminal, and user account information of a source user terminal from the source user terminal; determining, by the server, a risk level of the instant messaging message according to a preset rule and the user account information of the source user terminal; and if the risk level of the instant messaging message reaches a first risk level, transmitting, by the server when, the instant messaging message and preset pre-warning information to the destination user terminal according to the user account information of the destination user terminal, wherein the pre-warning information comprises security prompt information which is used for prompting a user of the destination user terminal to notice a security risk of the instant messaging message. An instant messaging message processing device is also disclosed.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: September 12, 2017
    Assignee: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
    Inventors: Yanping Tang, Meng Chen, Rong Chen, Yuanbin Chen, Zengxin Sun, Feifei Liu, Liang Dong, Dechun Li
  • Publication number: 20170065674
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 9, 2017
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • Publication number: 20160328699
    Abstract: A method and an apparatus for processing data are provided. The method includes: receiving, through a network, a data processing request sent by a first device, where the first device is connected to the network via a wireless access point; obtaining a distance value between the first device and the wireless access point in a case that the wireless access point is a credit access point for the first device; calculating, based on the distance value between the first device and the wireless access point, a credit value associated with the first device in a case that the distance value exceeds a preset distance threshold; and accepting the data processing request in a case that the credit value is greater than or equal to a credit threshold.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Applicant: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
    Inventors: Rong CHEN, Meng CHEN, Yuanbin CHEN, Kuan LIU, Liang DONG, Dechun LI, Feifei LIU, Chuansheng YU
  • Patent number: 9351165
    Abstract: An identity verifying method, an account acquiring method, a mobile terminal, and a storage medium are disclosed, and the account acquiring method includes: receiving, by a first mobile terminal, a user operation of accepting identity verification on the first mobile terminal, playing voice information which is stored in the first mobile terminal and has a correspondence relationship with a user account of a user of the first mobile terminal, and meanwhile collecting voice data of the played voice information using voice receiving means; sending, by the first mobile terminal, verification information comprising the user account and the voice data to a server to allow the server to determine whether the user passes the identity verification according to the verification information; and receiving, by the first mobile terminal, an identity verification result returned by the server. Thus, the voice information is used for identity verification.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 24, 2016
    Assignee: Tencent Technology (Shenzhen) Company Limited
    Inventors: Liang Dong, Meng Chen, Rong Chen, Yuanbin Chen, Dechun Li, Feifei Liu, Zengxin Sun, Yanping Tang
  • Publication number: 20150341795
    Abstract: An instant messaging message processing method is disclosed and includes: receiving, by a server, an instant messaging message, user account information of a destination user terminal, and user account information of a source user terminal from the source user terminal; determining, by the server, a risk level of the instant messaging message according to a preset rule and the user account information of the source user terminal; and if the risk level of the instant messaging message reaches a first risk level, transmitting, by the server when, the instant messaging message and preset pre-warning information to the destination user terminal according to the user account information of the destination user terminal, wherein the pre-warning information comprises security prompt information which is used for prompting a user of the destination user terminal to notice a security risk of the instant messaging message. An instant messaging message processing device is also disclosed.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Inventors: Yanping Tang, Meng Chen, Rong Chen, Yuanbin Chen, Zengxin Sun, Feifei Liu, Liang Dong, Dechun Li
  • Publication number: 20150264574
    Abstract: An identity verifying method, an account acquiring method, a mobile terminal, and a storage medium are disclosed, and the account acquiring method includes: receiving, by a first mobile terminal, a user operation of accepting identity verification on the first mobile terminal, playing voice information which is stored in the first mobile terminal and has a correspondence relationship with a user account of a user of the first mobile terminal, and meanwhile collecting voice data of the played voice information using voice receiving means; sending, by the first mobile terminal, verification information comprising the user account and the voice data to a server to allow the server to determine whether the user passes the identity verification according to the verification information; and receiving, by the first mobile terminal, an identity verification result returned by the server. Thus, the voice information is used for identity verification.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 17, 2015
    Inventors: Liang DONG, Meng CHEN, Rong CHEN, Yuanbin CHEN, Dechun LI, Feifei LIU, Zengxin SUN, Yanping TANG
  • Publication number: 20150004172
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Application
    Filed: September 10, 2014
    Publication date: January 1, 2015
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • Publication number: 20130243782
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-I or angiotensin II.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 19, 2013
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • Patent number: 8414891
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: April 9, 2013
    Assignee: The Johns Hopkins University
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • Patent number: 8354521
    Abstract: This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPAR?, and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed herein is a novel polypeptide coactivator of PPAR?, and fragments thereof, which possess coactivator or corepressor activity. Also related are nucleotide sequences which express these polypeptides. Also disclosed is an interfering RNA that may be used to inhibit adipogenesis.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: January 15, 2013
    Assignee: Saint Louis University
    Inventor: Dechun Li
  • Patent number: 8329177
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 11, 2012
    Assignee: The John Hopkins University
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • Publication number: 20120141489
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Application
    Filed: December 22, 2011
    Publication date: June 7, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Roger JOHNS, Xingwu TENG, Dechun LI
  • Publication number: 20120039839
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Application
    Filed: August 17, 2011
    Publication date: February 16, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Roger Johns, Xingwu Teng, Dechun LI
  • Patent number: 8080533
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: December 20, 2011
    Assignee: The Johns Hopkins University
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • Publication number: 20110014275
    Abstract: This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPAR?, and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed herein is a novel polypeptide coactivator of PPAR?, and fragments thereof, which possess coactivator or corepressor activity. Also related are nucleotide sequences which express these polypeptides. Also disclosed is an interfering RNA that may be used to inhibit adipogenesis.
    Type: Application
    Filed: August 30, 2010
    Publication date: January 20, 2011
    Applicant: Saint Louis University
    Inventor: Dechun Li
  • Publication number: 20110008349
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Application
    Filed: February 2, 2010
    Publication date: January 13, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Roger JOHNS, Xingwu TENG, Dechun LI
  • Patent number: 7834140
    Abstract: This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPAR?. and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed herein is a novel polypeptide coactivator of PPAR?, and fragments thereof, which possess coactivator or corepressor activity. Also related are nucleotide sequences which express these polypeptides. Also disclosed is an interfering RNA that may be used to inhibit adipogenesis.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: November 16, 2010
    Assignee: Saint Louis University
    Inventor: Dechun Li
  • Patent number: 7671037
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: March 2, 2010
    Assignee: The Johns Hopkins University
    Inventors: Roger Johns, Xingwu Teng, Dechun Li